5323212026-11-025323212026-11-022026-11-02iso4217:INRxbrli:pure532321ZYDUS LIFESCIENCES LIMITEDZYDUSLIFENOTLISTEDINE010B01027Updatefalse2026-11-0201:39:002024-09-172026-06-292026-11-02Acquisition (including agreement to acquire)In our earlier intimation dated August 23, 2024, Zydus Lifesciences Limited (“the Company”) intimated that the Company through its wholly owned subsidiary has acquired 50% stake of Sterling Biotech Limited (“SBL”). Active Pharmaceutical Ingredients (“API”) business of SBL is an excellent strategic fit for the Company given that it has fermentation-based products portfolio with a manufacturing facility at Masar (near Vadodara, Gujarat which is in proximity to the Company’s existing facility at Dabhasa) and can meet our strategic and commercial objectives. Therefore, while acquiring a 50% stake from the shareholders of SBL, the Company had negotiated for the right to acquire the Target Business of SBL at a pre-defined value. This right has been exercised by the Company. The Board of Directors of the Company at their meeting held today i.e. September 17, 2024 have approved a Business Transfer Agreement (“BTA”) to purchase the API business (“the Target Business”) of SBL, on a going concern basis, on slump sale basis, without values being assigned to individual assets and liabilities, on cash-free and debt-free basis at a pre-defined lump-sum consideration of Rs. 840 mio. (Rupees Eight Hundred Forty Million only), subject to certain conditions precedent and closing date adjustments as provided in the BTA, with effect from such date, and in such manner and on the terms and conditions as mentioned in the BTA. The Target Business of SBL consists of a portfolio of fermentation-based API products like Lovastatin, Daunorubicin, Doxorubicin and Epirubicin.Transaction CompletedYes16700000002026-11-021